All In Biotech

Drug Trial Radar · NCT05159245

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs

The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to Determine the Efficacy in Treatment of Advanced Cancers With a Known Molecular Profile

Last checked: Nov 19, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

250

Planned (sponsor's estimate)

Start

Dec 10, 2021

Primary completion

Nov 25, 2031

Study completion Nov 25, 2032

Sponsor

Lead sponsor
Helsinki University Central HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 16, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 100 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a prospective non-randomized national clinical phase 2 trial that aims to determine the efficacy and toxicity of targeted anticancer drugs or combinations that are approved or under review by EMA, FDA or PMDA and are used for treatment of patients with advanced cancer with a potentially actionable variant as revealed by a genomic, RNA-molecular or protein expression test.

Conditions

  • Advanced Cancer
  • Solid Tumor
  • Haematological Malignancy

Interventions

  • AlectinibDrug

    ALK

  • CobimetinibDrug

    MEK1, MEK2

  • VismodegibDrug

    Hedgehog

  • Trastuzumab+PertuzumabDrug

    HER2

  • EntrectinibDrug

    NTRK/ ROS1, ALK

  • AtezolizumabDrug

    PD-L1

  • VemurafenibDrug

    BRAF V600

  • RegorafenibDrug

    KIT/BRAF, RET

  • ApalutamideDrug

    AR

  • AbemaciclibDrug

    CDK4/6

  • TepotinibDrug

    MET ex14

  • DabrafenibDrug

    RAF

  • TrametinibDrug

    MEK1, MEK2

  • Dabrafenib+TrametinibDrug

    RAF, MEK1, MEK2

  • PemigatinibDrug

    FGFR2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Disease control rateTime frame: 16 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Kuopio University Hospital

    Kuopio, Finland · Recruiting

  • Oulu University Hospital OYS Cancer Center

    Oulu, Finland · Recruiting

  • Tampere University Hospital Department of Oncology

    Tampere, Finland · Recruiting

  • Turku University Hospital Cancer Centre

    Turku, Southwest Finland, Finland · Recruiting

  • Helsinki University Hospital Comprehensive Cancer Center

    Helsinki, Uusimaa, Finland · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.